Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09RLQ
|
|||
| Former ID |
DNCL002288
|
|||
| Drug Name |
CDX-1127
|
|||
| Indication | leukaemia [ICD-11: 2A60-2B33] | Phase 1 | [1] | |
| Lymphoma [ICD-11: 2A80-2A86] | Phase 1 | [1] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Phase 1 | [1] | ||
| Company |
Celldex Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | T-cell activation antigen CD27 (CD27) | Target Info | Modulator | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| IL4 Signaling Pathway | ||||
| Reactome | TNFs bind their physiological receptors | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02284971) Pilot Study of SBRT and CDX-1127 in Prostate Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Celldex Therapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.